FY2025 EPS Estimates for PTCT Reduced by Cantor Fitzgerald

Key Points

• Cantor Fitzgerald has downgraded its FY2025 earnings estimate for PTC Therapeutics to $8.16 per share, down from $8.20, while maintaining an "Overweight" rating and a price target of $120.00.
• While Cantor Fitzgerald revised its estimates, other firms like Citigroup and Bank of America have increased their price targets for PTC Therapeutics, highlighting a range of market confidence with various ratings.
• PTC Therapeutics reported a strong quarterly earnings result, with $10.04 EPS, significantly exceeding the consensus estimate, though the company's revenue decreased 9.6% year-over-year.

PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) - Research analysts at Cantor Fitzgerald dropped their FY2025 earnings per share estimates for PTC Therapeutics in a report issued on Tuesday, July 29th. Cantor Fitzgerald analyst K. Kluska now anticipates that the biopharmaceutical company will post earnings per share of $8.16 for the year, down from their prior estimate of $8.20. Cantor Fitzgerald has a "Overweight" rating and a $120.00 price target on the stock. The consensus estimate for PTC Therapeutics' current full-year earnings is ($4.52) per share.

PTC Therapeutics (NASDAQ:PTCT - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The biopharmaceutical company reported $10.04 EPS for the quarter, topping analysts' consensus estimates of $0.85 by $9.19. The business had revenue of $1.18 billion during the quarter, compared to analysts' expectations of $437.16 million. PTC Therapeutics had a negative return on equity of 78.56% and a net margin of 33.56%. PTC Therapeutics's quarterly revenue was down 9.6% on a year-over-year basis. During the same quarter last year, the company posted ($1.20) earnings per share.

Other equities research analysts also recently issued reports about the stock. Wells Fargo & Company raised their price objective on shares of PTC Therapeutics from $74.00 to $78.00 and gave the stock an "overweight" rating in a research report on Tuesday, July 29th. Barclays raised their price objective on shares of PTC Therapeutics from $42.00 to $46.00 and gave the stock an "equal weight" rating in a research report on Tuesday, July 29th. Citigroup raised their price objective on shares of PTC Therapeutics from $40.00 to $50.00 and gave the stock a "neutral" rating in a research report on Monday, July 28th. JPMorgan Chase & Co. dropped their price target on shares of PTC Therapeutics from $75.00 to $67.00 and set an "overweight" rating for the company in a research report on Wednesday, May 7th. Finally, UBS Group lifted their price target on shares of PTC Therapeutics from $71.00 to $80.00 and gave the company a "buy" rating in a research report on Tuesday, July 29th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $69.38.

PTC Therapeutics Trading Up 0.0%

PTCT stock traded up $0.02 during mid-day trading on Wednesday, hitting $52.13. 1,020,621 shares of the company were exchanged, compared to its average volume of 1,123,253. The business has a 50 day simple moving average of $49.21 and a 200-day simple moving average of $48.75. The stock has a market capitalization of $4.13 billion, a PE ratio of 8.01 and a beta of 0.54. PTC Therapeutics has a 1-year low of $29.01 and a 1-year high of $58.38.

Institutional Trading of PTC Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of PTCT. Sterling Capital Management LLC increased its holdings in PTC Therapeutics by 424.4% in the fourth quarter. Sterling Capital Management LLC now owns 645 shares of the biopharmaceutical company's stock valued at $29,000 after purchasing an additional 522 shares during the period. Quantbot Technologies LP increased its holdings in PTC Therapeutics by 545.5% in the first quarter. Quantbot Technologies LP now owns 652 shares of the biopharmaceutical company's stock valued at $33,000 after purchasing an additional 551 shares during the period. PNC Financial Services Group Inc. boosted its position in PTC Therapeutics by 84.2% during the first quarter. PNC Financial Services Group Inc. now owns 700 shares of the biopharmaceutical company's stock valued at $36,000 after acquiring an additional 320 shares during the last quarter. GAMMA Investing LLC boosted its position in PTC Therapeutics by 86.3% during the first quarter. GAMMA Investing LLC now owns 952 shares of the biopharmaceutical company's stock valued at $49,000 after acquiring an additional 441 shares during the last quarter. Finally, BI Asset Management Fondsmaeglerselskab A S bought a new stake in PTC Therapeutics during the first quarter valued at $61,000.

Insider Buying and Selling at PTC Therapeutics

In other news, CFO Pierre Gravier sold 2,516 shares of the company's stock in a transaction on Tuesday, July 15th. The shares were sold at an average price of $49.46, for a total transaction of $124,441.36. Following the completion of the transaction, the chief financial officer directly owned 71,920 shares in the company, valued at approximately $3,557,163.20. This represents a 3.38% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Mark Elliott Boulding sold 883 shares of the company's stock in a transaction on Friday, May 16th. The stock was sold at an average price of $46.02, for a total transaction of $40,635.66. Following the transaction, the vice president owned 103,901 shares of the company's stock, valued at $4,781,524.02. This trade represents a 0.84% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 5,328 shares of company stock valued at $254,158 over the last 90 days. Corporate insiders own 5.50% of the company's stock.

PTC Therapeutics Company Profile

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.